Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab

BACKGROUND: Docetaxel in combination with two HER2-directed therapies, trastuzumab and pertuzumab, is the current standard frontline therapy for patients with metastatic HER2-positive breast cancer. Ado-trastuzumab (T-DM1), an antibody-drug conjugate of trastuzumab and a cytotoxic microtubule-inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Rabadi, Luai S., Cook, Madeline M., Kaempf, Andy J., Saraceni, Megan M., Savin, Michael A., Mitri, Zahi I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8549287/
https://www.ncbi.nlm.nih.gov/pubmed/34706686
http://dx.doi.org/10.1186/s12885-021-08894-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8549287/
https://www.ncbi.nlm.nih.gov/pubmed/34706686
http://dx.doi.org/10.1186/s12885-021-08894-2

Ejemplares similares